News Room

  • Co-Diagnostics, Inc. to Use IPO Proceeds to Expand Operations

    SALT LAKE CITY, UTAH (PRWEB) JULY 17, 2017 Salt Lake City, UT – July 17, 2017 – Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has developed and intends both to manufacture and sell reagents used for diagnostic tests, has completed its initial public offering and started trading on the NASDAQ […]
  • Co-Diagnostics, Inc. Announces Pricing of IPO

    Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests, announced today that its initial public offering of 1,178,532 shares of common stock has been priced at $6.00 per share. Total gross proceeds from the offering will be $7,071,192. […]
  • Eureka Labs hosts Co-Diagnostics and touts partnership

    Following a visit to Eureka Medical Laboratories (EML) in Georgetown, Guyana, EML was featured in an article in the Guyana Times. In speaking of the event, Co-Diagnostics president and CEO Dwight Egan said: “We plan to make available a large menu of tests over the coming year that will enable the citizens of Guyana to […]
  • Co-Diagnostics mention in local press

    Co-Diagnostics received a mention from a local news outlet for being on the front lines of the war on Zika. The full text can be found by clicking the headline here: ‘It’s a full-frontal attack’: Utah companies, universities continue Zika research    
  • Co-Diagnostics Presents Technology to Woodlands Hospital, Guyana

    Co-Diagnostics CEO Dwight Egan is currently visiting the countries of Guyana and Trinidad and Tobago, where he has been invited to introduce our revolutionary testing solutions to select hospitals and laboratories in those regions. On October 24, 2016, Mr. Egan and two members of our science team presented Co-Diagnostics’ Zika Virus Rapid Test™  to staff and press […]
  • Patent Approved for HotStart Technology

    We are happy to announce that earlier this month the company received notification that our patent titled “Nucleic Acid Hotstart Technology” has been approved by the US Patent office. Once the patent has been officially granted, we will issue a press release containing the US Patent Number. The patent abstract reads: “The present invitation relates […]
  • Fox 13 broadcast: Utah based company developing a test to detect Zika Virus

    As news of our work on Zika virus continues to generate interest, another story was recorded and aired yesterday. This coverage can be found here.
  • Spread of Zika virus prompting Utah researchers to find treatment

    Following our recent press release, the local NBC affiliate station spent some time in our lab to discuss the efforts of our team of experts to develop a diagnostic for Zika virus. The story can be found here.
  • Co-Diagnostics Prepares Zika Virus Diagnostics Proposal

    See original release on PRWeb. SANDY, UT (PRWEB) FEBRUARY 04, 2016 Co-Diagnostics, Inc. announced today that the company has begun the preliminary test design process to develop a diagnostic for the mosquito-borne Zika virus and has prepared proposals to be submitted to the governments of affected Latin American countries. Zika virus is rarely fatal, but […]
  • Expanded ISO certification received

    On January 14th, the company received official certificates for ISO 13485 : 2003 and ISO 9001 : 2008, with an expanded scope from the previous certification announced in 2015. The registration numbers, no. 10013216 MP23 and no. 10013216 QM08 respectively, remain unchanged from the previous certifications. Whereas the previous certifications were granted to DNA Logix […]
  • 2015 SALSS Presentation

    View Release on PRWeb Co-Diagnostics CEO to present at 2015 SALSS in Stockholm, Sweden SANDY, UT (PRWEB) AUGUST 20, 2015 Co-Diagnostics CEO Dwight Egan will be a presenter at the 2015 Swedish-American Life Science Summit, taking place in August 19-21 in Stockholm, Sweden, the company confirmed today. The SALSS began 11 years ago as a […]
  • Biosearch & Co-Diagnostics

    View release on Genomeweb View Release on PRWEB Biosearch and Co-Diagnostics Sign Cooperative Primers Agreement Salt Lake City, UT (PRWEB) April 01, 2015 Biosearch Technologies and Co-Diagnostics announced today an agreement allowing Biosearch to make, use, market and sell Co-Diagnostics’ CoPrimers™ technology to research institutions. The agreement also licenses CoPrimers™ technology to Biosearch for its […]
  • World TB Day 2015

    Dear Co-Diagnostics shareholders, supporters, and followers, It is estimated that nearly 9 million people worldwide contract tuberculosis each year. In 2014, 1.3 million did not survive. Every year on March 24th, the nations of the world come together to mark World TB day, a public health campaign started by the World Health Organization to recognize […]
  • Malaria Test Ready for Validation

    We are pleased to announce that Co-Diagnostics’ real-time PCR test for malaria, built on our patent-pending CoPrimers™ technology, is ready for in-field validation. See official press release here.
  • Co-Diagnostics Acquires DNA Logix and Co-Diagnostics HBDC

    Dear shareholders and customers of Co-Diagnostics, We are pleased to announce that on December 31, 2014, the Management of Co-Diagnostics Inc signed an agreement with DNA Logix Inc. for the latter company to become a wholly-owned subsidiary. DNA Logix is ISO-certified for design, development, testing, and manufacturing of tuberculosis tests and their components. Founded by Dr. […]